Vimarsana
Biggest News Aggregation in the World

Page 7 - Allogeneic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogeneic Today - Breaking & Trending Today

Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval - Vimarsana News

Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and... | April 17, 2023

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses - Vimarsana News

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell... | April 13, 2023

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease - Vimarsana News

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice... | April 13, 2023

Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Vimarsana News

Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) -ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE)

Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference - Vimarsana News

Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive... | April 13, 2023